University of Pennsylvania Center for Studies of Addiction
Philadelphia, Pennsylvania, 19104, United States
NCT Number: NCT01821560
The proposed project will utilize perfusion functional magnetic resonance imaging (fMRI), a functional candidate gene association approach (of dopaminergic addictions-targeted polymorphisms), and the dopamine-modulating and gamma-aminobutyric acid (GABA) B receptor agonist, baclofen, to examine the brain and behavioral responses in smokers to appetitive smoking reminders (cues that motivate continued smoking and relapse). These studies will provide a means to identify an appetitive cue-sensitive pharmacologic-responsive endophenotype. Once brain/behavioral/genetic endophenotypes can be determined prior to treatment, smoking cessation treatments can be structured to meet individual needs, which will significantly improve treatment outcome.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Phase 2
Philadelphia, Pennsylvania, 19104, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Kemstro, Lioresal, Liofen, Gablofen, Beklo
Time frame: 3 weeks (Scan Day 1, week1- Scan Day 2, week 4)
Cigarettes per day at Scan Day 2; Baclofen group vs. placebo group
University of Pennsylvania
Other
Baclofen Effects on Brain and Behavior in Cigarette Smokers
Acronym: BAC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07737288
Behavior, Chemically-Induced Disorders
Izmir, Turkey (Türkiye)
View Trial DetailsNCT01036685
Chemically-Induced Disorders, Drug Abuse
Baltimore, Maryland, United States
View Trial DetailsNCT01867411
Behavior, Chemically-Induced Disorders
Baltimore, Maryland, United States
View Trial DetailsNCT04188873
Chemically-Induced Disorders, Mental Disorders
Madison, Wisconsin, United States
View Trial Details